KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures. PMID 35908275 · Epilepsia Open · 2022-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Intravenous ferric derisomaltose for iron-deficiency anemia associated with gastrointestinal diseases: a single-arm, randomized, uncontrolled, open-label study. PMID 35867202 · Int J Hematol · 2022-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats. PMID 35866633 · Clin Trials · 2022-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and tolerability of brivaracetam monotherapy in childhood and juvenile absence epilepsy: An innovative adaptive trial design. PMID 35844134 · Epilepsia Open · 2022-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. PMID 35653225 · Hematol Oncol · 2022-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia. PMID 35635742 · J Oncol Pharm Pract · 2022-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. PMID 35471602 · Cancer Immunol Immunother · 2022-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder. PMID 35402894 · Sleep Med X · 2022-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Paired vagus nerve stimulation for treatment of upper extremity impairment after stroke. PMID 35377261 · Int J Stroke · 2022-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial. PMID 35276329 · Clin Gastroenterol Hepatol · 2022-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America. PMID 35192778 · Hematology · 2022-Dec The record describes an observational study, not a randomized controlled trial. While it reports original efficacy and safety data for venetoclax-based combinations in AML (an oncology indication), the study design is explicitly observational/non-randomized. Therefore, it does not meet the core requirement of being a Phase III/IIIb or Phase II/III randomized trial.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis. PMID 35145039 · Thorax · 2022-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'. PMID 32988847 · Ann Rheum Dis · 2022-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Response to: 'Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'' by Satis et al. PMID 32988842 · Ann Rheum Dis · 2022-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. PMID 36135061 · Curr Oncol · 2022-Aug-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis. PMID 36145549 · Pharmaceutics · 2022-Aug-27 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. PMID 36077679 · Cancers (Basel) · 2022-Aug-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Slowly absorbable mesh versus standard care in the management of contaminated midline incisional hernia (COMpACT-BIO): a multicentre randomised controlled phase III trial including a health economic evaluation. PMID 36008058 · BMJ Open · 2022-Aug-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The primary pharmacology of ceftazidime/avibactam: in vitro translational biology. PMID 35665807 · J Antimicrob Chemother · 2022-Aug-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial. PMID 35219277 · Clin Infect Dis · 2022-Aug-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. PMID 34718468 · Clin Infect Dis · 2022-Aug-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The odyssey of pacritinib in myelofibrosis. PMID 35622972 · Blood Adv · 2022-Aug-23 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H
仅历史库存 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice. PMID 35839430 · J Clin Oncol · 2022-Aug-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Current Evidence of a Deintensification Strategy for Patients with HPV-Related Oropharyngeal Cancer. PMID 36010959 · Cancers (Basel) · 2022-Aug-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
SINFONIA study protocol: a phase II/III randomised controlled trial examining benefits of guided online group singing in people with chronic obstructive pulmonary disease and interstitial lung disease and their carers. PMID 35974347 · Respir Res · 2022-Aug-16 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. PMID 34907081 · Clin Cancer Res · 2022-Aug-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Correction: Cliniclal benefit of 1-year certolizumab pegol(CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritiswas observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. PMID 38743655 · Ann Rheum Dis · 2022-Aug-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Attractive targeted sugar bait phase III trials in Kenya, Mali, and Zambia. PMID 35945599 · Trials · 2022-Aug-09 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial. PMID 35954471 · Cancers (Basel) · 2022-Aug-05 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Transplantation of mesenchymal stem cells for prevention of acute myocardial infarction induced heart failure: study protocol of a phase III randomized clinical trial (Prevent-TAHA8). PMID 35927674 · Trials · 2022-Aug-04 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Routine data-based quality indicators for the treatment of gonarthrosis and coxarthrosis patients in the ambulatory care sector - A study protocol for a cluster-randomised pilot trial to evaluate the MobilE-ARTH study. PMID 35927649 · BMC Musculoskelet Disord · 2022-Aug-04 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program. PMID 34897366 · Rheumatology (Oxford) · 2022-Aug-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). PMID 35294546 · Clin Cancer Res · 2022-Aug-02 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial. PMID 35969402 · JAMA Netw Open · 2022-Aug-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments. PMID 35915506 · Trials · 2022-Aug-01 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis: short-term and long-term outcomes from the CHECK study - protocol for a randomised, multicentre, phase 3 trial. PMID 35914916 · BMJ Open · 2022-Aug-01 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Glutamic acid decarboxylase immunotherapy for type 1 diabetes. PMID 35776501 · Curr Opin Endocrinol Diabetes Obes · 2022-Aug-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. PMID 36644205 · Atheroscler Plus · 2022-Aug 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety Profile of Mutant EGFR-TK Inhibitors in Advanced Non-Small Cell Lung Cancer: A Meta-analysis. PMID 36426108 · Fed Pract · 2022-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial. PMID 36128589 · World J Oncol · 2022-Aug 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups. PMID 36046700 · Open Forum Infect Dis · 2022-Aug 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019. PMID 36043180 · Open Forum Infect Dis · 2022-Aug 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients. PMID 36042753 · Indian J Crit Care Med · 2022-Aug 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program. PMID 36039153 · Kidney Med · 2022-Aug 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies. PMID 36016762 · Kidney Med · 2022-Aug 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ozanimod: A Review in Ulcerative Colitis. PMID 35994200 · Drugs · 2022-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. PMID 35964548 · ESMO Open · 2022-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups. PMID 35895098 · Lung · 2022-Aug The study is a randomized, Phase 3 subgroup analysis of a drug (gefapixant) for chronic cough, which is not an oncology condition. It does not use a time-to-event endpoint (like OS, PFS, etc.). Therefore, it does not meet the core eligibility criteria for the oncology KM digitization cohort.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity. PMID 35860434 · JHEP Rep · 2022-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia. PMID 35852098 · Future Oncol · 2022-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -